BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 36989976)

  • 21. Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction.
    Scorsetti M; Cozzi L; Navarria P; Fogliata A; Rossi A; Franceschini D; De Rose F; Franzese C; Carlo-Stella C; Santoro A
    Radiat Oncol; 2020 Jan; 15(1):12. PubMed ID: 31931861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients.
    de Jong BA; Battinelli C; Free J; Wagenaar D; Engwall E; Janssens G; Langendijk JA; Korevaar EW; Both S
    Med Phys; 2023 Mar; 50(3):1305-1317. PubMed ID: 36373893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of RBE variations on risk estimates of temporal lobe necrosis in patients treated with intensity-modulated proton therapy for head and neck cancer.
    Engeseth GM; Hysing LB; Yepes P; Pettersen HES; Mohan R; Fuller CD; Stokkevåg CH; Wu R; Zhang X; Frank SJ; Gunn GB
    Acta Oncol; 2022 Feb; 61(2):215-222. PubMed ID: 34534047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.
    Jakobi A; Stützer K; Bandurska-Luque A; Löck S; Haase R; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
    Acta Oncol; 2015; 54(9):1658-64. PubMed ID: 26340301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantification of biological range uncertainties in patients treated at the Krakow proton therapy centre.
    Garbacz M; Gajewski J; Durante M; Kisielewicz K; Krah N; Kopeć R; Olko P; Patera V; Rinaldi I; Rydygier M; Schiavi A; Scifoni E; Skóra T; Skrzypek A; Tommasino F; Rucinski A
    Radiat Oncol; 2022 Mar; 17(1):50. PubMed ID: 35264184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiobiological and dosimetric impact of RayStation pencil beam and Monte Carlo algorithms on intensity-modulated proton therapy breast cancer plans.
    Rana S; Greco K; Samuel EJJ; Bennouna J
    J Appl Clin Med Phys; 2019 Aug; 20(8):36-46. PubMed ID: 31343826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linear energy transfer-guided optimization in intensity modulated proton therapy: feasibility study and clinical potential.
    Giantsoudi D; Grassberger C; Craft D; Niemierko A; Trofimov A; Paganetti H
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):216-22. PubMed ID: 23790771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of breathing motion and a variable relative biological effectiveness in proton therapy of left-sided breast cancer.
    Ödén J; Toma-Dasu I; Eriksson K; Flejmer AM; Dasu A
    Acta Oncol; 2017 Nov; 56(11):1428-1436. PubMed ID: 28826308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incorporation of the LETd-weighted biological dose in the evaluation of breast intensity-modulated proton therapy plans.
    Liu C; Zheng D; Bradley JA; Mailhot Vega RB; Zhang Y; Indelicato DJ; Mendenhall N; Liang X
    Acta Oncol; 2021 Feb; 60(2):252-259. PubMed ID: 33063569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy.
    Loap P; Orlandi E; De Marzi L; Vitolo V; Barcellini A; Iannalfi A; Dendale R; Kirova Y; Mirandola A
    Acta Oncol; 2022 Aug; 61(8):979-986. PubMed ID: 35668710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beam angle comparison for distal esophageal carcinoma patients treated with intensity-modulated proton therapy.
    Feng H; Sio TT; Rule WG; Bhangoo RS; Lara P; Patrick CL; Korte S; Fatyga M; Wong WW; Schild SE; Ashman JB; Liu W
    J Appl Clin Med Phys; 2020 Nov; 21(11):141-152. PubMed ID: 33058523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of the uncertainties of a biological model and their impact on variable RBE proton treatment plan optimization.
    Resch AF; Landry G; Kamp F; Cabal G; Belka C; Wilkens JJ; Parodi K; Dedes G
    Phys Med; 2017 Apr; 36():91-102. PubMed ID: 28410691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proton Treatment Techniques for Posterior Fossa Tumors: Consequences for Linear Energy Transfer and Dose-Volume Parameters for the Brainstem and Organs at Risk.
    Giantsoudi D; Adams J; MacDonald SM; Paganetti H
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):401-410. PubMed ID: 27986346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosimetric comparison between carbon, proton and photon radiation for renal retroperitoneal soft tissue sarcoma recurrence or metastasis after radical nephrectomy.
    Ming X; Wang W; Shahnazi K; Sun J; Zhang Q; Li P; Hong Z; Sheng Y
    Int J Radiat Biol; 2022; 98(2):183-190. PubMed ID: 34802361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploration and application of phenomenological RBE models for proton therapy.
    Rørvik E; Fjæra LF; Dahle TJ; Dale JE; Engeseth GM; Stokkevåg CH; Thörnqvist S; Ytre-Hauge KS
    Phys Med Biol; 2018 Sep; 63(18):185013. PubMed ID: 30102240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis.
    Widesott L; Pierelli A; Fiorino C; Lomax AJ; Amichetti M; Cozzarini C; Soukup M; Schneider R; Hug E; Di Muzio N; Calandrino R; Schwarz M
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1589-600. PubMed ID: 21167651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential skin morbidity reduction with intensity-modulated proton therapy for breast cancer with nodal involvement.
    Fellin F; Iacco M; D'Avino V; Tommasino F; Farace P; Palma G; Conson M; Giacomelli I; Zucchetti C; Falcinelli L; Amichetti M; Aristei C; Cella L
    Acta Oncol; 2019 Jun; 58(6):934-942. PubMed ID: 30938217
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparing biological effectiveness guided plan optimization strategies for cranial proton therapy: potential and challenges.
    Hahn C; Heuchel L; Ödén J; Traneus E; Wulff J; Plaude S; Timmermann B; Bäumer C; Lühr A
    Radiat Oncol; 2022 Oct; 17(1):169. PubMed ID: 36273132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disregarding RBE variation in treatment plan comparison may lead to bias in favor of proton plans.
    Wedenberg M; Toma-Dasu I
    Med Phys; 2014 Sep; 41(9):091706. PubMed ID: 25186381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams.
    Underwood TS; Voog JC; Moteabbed M; Tang S; Soffen E; Cahlon O; Lu HM; Zietman AL; Efstathiou JA; Paganetti H
    Acta Oncol; 2017 Apr; 56(4):575-581. PubMed ID: 28075206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.